AstraZeneca Pharma India surrenders marketing authorisation for specific indication of Olaparib
Bangalore: AstraZeneca Pharma India Limited has surrendered its marketing authorisation for Olaparib film-coated tablets 100mg and 150mg (Lynparza) for indication in combination with Abiraterone and Prednisone or Prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer.
Prostate cancer is a type of cancer that occurs in the prostate gland — a small, walnut-shaped gland in men that produces seminal fluid. It is one of the most common types of cancer among men, particularly those over the age of 50.
The Company had earlier received the marketing authorisation for the said medication in November 17, 2023.
However, in a recent statement, AstraZeneca confirmed that the company never marketed the said indication in India following the approval.
The decision to surrender the authorisation, the company clarified, was made purely for commercial reasons and is not related to any concerns regarding the efficacy or safety of the drug.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.